Navigation Links
Princess Margaret breast cancer research finds new drug target companion prognostic test for hormone therapy resistance
Date:4/1/2013

(TORONTO, Canada April 1, 2013) A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant.

Resistance to hormone therapy is reported in almost half of ER-positive breast cancer patients and no cure is currently available. The fact that the pathway, called Notch, is a drug target creates hope for a new therapy.

The findings, published online today in PNAS, the Proceedings of the National Academy of Sciences of the United States of America, "provide a new therapeutic target against hormone therapy-resistant breast cancers and a companion test to identify tumours that would become resistant" says Dr. Lupien, a scientist at the Ontario Cancer Institute, the research arm of the cancer centre, and an Assistant Professor in the Department of Medial Biophysics, University of Toronto. He specializes in epigenetics of hormone-dependent cancers the study of non-genetic determinants of cellular identity that can also be altered to initiate or modify disease.

"In studying the epigenetics of hormone therapy resistance, we discovered that breast cancer cells behave like a chameleon. Indeed, as the chameleon changes its skin colour to camouflage itself and evade predators," says Dr. Lupien, "breast cancer cells change the appearance of their DNA through epigenetics to evade, in this case, hormone therapy." In so doing, hormone therapy-resistant breast cancer cells highlight regions of their DNA related to the Notch pathway.

At the molecular level, the research team characterized the epigenetic appearances of the DNA of drug-resistant and drug-responsive breast cancer cells. The team discovered that the Notch signaling pathway plays the predominant role in drug-resistant breast cancer cells even if cells remain positive for ER.

"This is a highly promising discovery that could rapidly translate in the clinic. Drugs against the Notch pathway are available." says Dr. Lupien. The key will be to test the efficacy of these drugs against hormone therapy resistance in breast cancer.


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network
Source:Eurekalert

Related medicine news :

1. HRH Crown Princess Mary of Denmark announced as patron of Australian and Danish twin registries
2. Blue Deer Center in Margaretville, New York, Welcomes Theodore Finkle as New Center Manager
3. Plant Spirit Medicine Healer Training Begins March 2013 at Blue Deer Center in Margaretville, NY
4. ASH honors Margaret A. Goodell, Ph.D., with 2012 William Dameshek Prize
5. More Evidence Shows Hormone Therapy May Increase Breast Cancer Risk
6. When Breast Cancer Spreads to Lungs, Surgery May Increase Survival
7. Estrogen plus progestin use linked with increased breast cancer incidence and mortality
8. Author of new breast cancer study comments on its findings of increased risk
9. University of Maryland breast cancer research pioneer Dr. Angela Brodie named AACR Academy Fellow
10. Associated Plastic Surgeons & Consultants Reports that Insurance Denied Payment for Bilateral Breast Reconstruction Following Mastectomy
11. Newly Release Video Reveals Technical aspects of Advanced Breast Augmentation Surgery The Cold-Subfascial Breast Augmentation TM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... The OSHA Training Center at ... Center headquartered in Northern California, has issued an important reminder to employers to ... Employers with workers exposed to high temperatures should establish a complete heat ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology: